Dong-Hua Yang
Overview
Explore the profile of Dong-Hua Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
2562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Chen Z, Chen L, Dong Q, Yang D, Zhang Q, et al.
Chin Med
. 2024 Aug;
19(1):119.
PMID: 39215362
Astragali radix (AR, namded Huangqi in Chinese) is the dried root of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. As a widely used ethnomedicine,...
2.
Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al.
Mol Cancer
. 2024 Aug;
23(1):175.
PMID: 39187850
In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies...
3.
Lu Q, Ambudkar S, Yang D
Drug Resist Updat
. 2024 Aug;
77:101135.
PMID: 39178712
No abstract available.
4.
Wan Y, Qi X, Lian Y, Liu Z, Wang H, Qiu Y, et al.
Cancer Lett
. 2024 Jun;
598:217094.
PMID: 38945204
Recent therapeutic strategies for the treatment of triple-negative breast cancer (TNBC) have shifted the focus from vascular growth factors to endothelial cell metabolism. This study highlights the underexplored therapeutic potential...
5.
Wu S, Wang H, Yang Q, Liu Z, Du J, Wang L, et al.
Cancer Lett
. 2024 Jun;
597:217058.
PMID: 38880226
Objective: N6-methyladenosine (M6A) is the most prevalent epigenetic alteration. Methyltransferase-like 3 (METTL3) is a key player in the control of M6A modification. Methyltransferase promote the processing of mature miRNA in...
6.
Huang Y, Qin Y, He Y, Qiu D, Zheng Y, Wei J, et al.
Drug Resist Updat
. 2024 Apr;
74:101082.
PMID: 38569225
Molecular targeted drugs and chimeric antigen receptor (CAR) T cell therapy represent specific biological treatments that have significantly improved the efficacy of treating hematologic malignancies. However, they face challenges such...
7.
Chen T, Xiao Z, Liu X, Wang T, Wang Y, Ye F, et al.
Pharmacol Res
. 2024 Feb;
202:107099.
PMID: 38342327
Cancer cells frequently develop resistance to chemotherapeutic therapies and targeted drugs, which has been a significant challenge in cancer management. With the growing advances in technologies in isolation and identification...
8.
Chen D, Xie Y, Cao L, Fleishman J, Chen Y, Wu T, et al.
Drug Resist Updat
. 2024 Feb;
73:101062.
PMID: 38330827
Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC) transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001. ABCC10/MRP7 is a 171 kDa...
9.
Luan Y, Li X, Luan Y, Luo J, Dong Q, Ye S, et al.
Mol Cancer
. 2024 Jan;
23(1):2.
PMID: 38178117
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced,...
10.